Created On: 2020-07-15
Record Count: 13
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 253
Product relates to brand name FuzeonÂ® in indications other than the treatment of HIV. Fuzeon was developed in collaboration with the Licensee, and is our only currently marketed product. Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41. The FDA approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.
Date U.S. Pat. No. 5,464,933 11/7/95 Synthetic Peptide Inhibitors of HIV Transmission 6/7/2013
U.S. Patent No. 6,133,418 10/17/00 Synthetic Peptide Inhibitors of HIV Transmission 11/17/2014
U.S. Patent No. 6,475,491 11/5/02 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/7/2015
U.S. Patent No. 6,861,059 3/1/05 Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations 9/9/2015
Canadian Patent No. 2,224,008 8/18/09 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/6/2016
U.S. Patent No. 6,281,331 8/28/01 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,015,881 1/18/00 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,824,783 11/30/04 Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission 11/30/2021
IPSCIO Record ID: 6950
IPSCIO Record ID: 1206
The Development and License Agreement has been amended several times; most recently in March 2007, the Agreement was amended to cover only the development and commercialization of Fuzeon.
The Licensor is a biopharmaceutical company primarily engaged in the commercialization of a new class of antiviral drug treatments called fusion inhibitors. Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, our first commercial product and our development-stage compound offer a novel mechanism of action to treat and potentially prevent the transmission of HIV.
IPSCIO Record ID: 26496
U.S. Patent No. 5,444,044- For: Synthetic Polypeptides As Inhibitors Of HIV-1
IPSCIO Record ID: 27851
IPSCIO Record ID: 26363
The patents covering a peptide product, known as BlockAide, for the treatment and prevention of HIV.
IPSCIO Record ID: 243453
Licensor grants a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Drug Candidates and Joint Products under Licensors part of the Joint Research Patents and any rights licensed by Licensor to Licensee in the License Agreement which also cover such Drug Candidate or Joint Products.
Licensee shall have the right to sublicense the rights granted in the Field to any third party.
Type II Drug Candidate shall mean any Peptide which is covered by the Licensors Patents and is identified by Licensor or Licensee after July 1, 1999.
'Peptide' shall mean a peptide, peptoid, or peptidomimetic of molecular weight greater than 2000 Daltons.
IPSCIO Record ID: 289184
The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.
Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.
7,250,421 – Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).
IPSCIO Record ID: 26110
Â· U.S. Patent No. 6,846,605 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (related to Case # CU9014H).
Â· U.S. Patent Application No. 11/044,224 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (Continuation application of Patent No. 6,846,605).
Â· Provisional Patent Application No. 60/742,191 Alpha-1-antitrypsin inhibition of disease and conditions mediated by binding to cell-associate actin (related to Case # CU1428H).
Â· Provisional Application No. 60/913,174 Title: Compositions and Methods of Use for AlphaÂAnti Trypsin Having No Significant Serine Protease Inhibitor Activity (CU1697H US).
Â· PCT Application No, PCT/US2006/061577 Title: Compositions and Methods For Treating Actin-Mediated Conditions (CU1428H).
Â· U.S. Patent Application No.11/719,200 Compositions and Methods For Treating Actin- Mediated Conditions (CU1428H US1).
Treatment of all viral infections including, without limitation, any and all mutations, strains, and subtypes, including future mutations, strains, and subtypes of: Human Immunodeficiency Virus (HIV) (including any viral infections reasonably and/or previously withheld by the University, when they become available); Human Papilloma Virus (HPV); Herpes Simplex Virus (HSV); Hepacivirus; Pestivirus; Avian influenza virus; Human influenza virus; Murray Valley encephalitis; St. Louis encephalitis.
IPSCIO Record ID: 2659
Savvy Â® (C31G vaginal gel) is a potential microbicide for the prevention of male-to-female transmission of HIV among women at high risk of infection. The active compound in Savvy is C31G, a broad-spectrum compound with antiviral, antibacterial and antifungal activity.
Product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally, including SavvyÂ®, which underwent Phase 3 clinical trials in Ghana and Nigeria for reduction in the transmission of Human Immunodeficiency Virus/Acquired Immunodeficiency Disease, or HIV/AIDS, both of which were suspended in 2005 and 2006 and terminated before completion, and is the subject to a Phase 3 contraception trial in the United States. While the Savvy Phase 3 contraception trial in the United States has been completed and the analysis of the results is expected to be completed by the end of 2009.
IPSCIO Record ID: 139546
IPSCIO Record ID: 3138
Licensed Product(s) means any material, composition, drug, transducing particle, or other product, the manufacture, use or sale of which would constitute, but for the license granted to the Company pursuant to this Agreement, an infringement of a claim of Patent Rights (infringement shall include, but is not limited to, direct, contributory, or inducement to infringe).
IPSCIO Record ID: 3900
The Company and Licensor have agreed, in principle, to an amendment to the existing Licensing Agreement to include additional virus types among the virus types the Company is permitted to manufacture, use, and offer for sale, and, Licensor has permitted the Company to use its nanomaterials to develop treatments for Dengue viruses, Ebola/Marburg viruses, and viruses causing viral Conjunctivitis (a disease of the eye), until such time as the Company and Licensor can complete an amendment to the Licensing Agreement to include these additional virus types we are permitted to manufacture, use and offer for sale.